Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial


I'm Interested

Trial ID: NCT05554380


This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has an AKT genetic change. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Targeted therapy, such as Ipatasertib, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of ipatasertib to paclitaxel in solid tumors with an AKT genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression). Researchers hope to learn if paclitaxel plus ipatasertib will shrink this type of cancer or stop its growth.

Official Title

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

Stanford Investigator(s)

James Ford
James Ford

Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics


Inclusion Criteria:

   - Patient must have enrolled onto EAY191 and must have been given a treatment assignment
   to ComboMATCH to EAY191-S3 based on the presence of an actionable mutation as defined
   in EAY191


   - Participants must be enrolled on the ComboMATCH Master Registration Trial EAY191

   - Participants must have an activating AKT mutation (a known mutation in AKT1, AKT2, or
   AKT3, a single nucleotide variant, insertion, or deletion) as determined by the
   ComboMATCH screening assessment


   - Participants must not have an activating KRAS, NRAS, HRAS, or BRAF mutation (a single
   nucleotide variant, insertion, or deletion) as determined by the ComboMATCH screening

   - Participants must have disease that can be safely biopsied and agree to a
   pre-treatment biopsy or have archival tissue available from within 12 months prior to
   the date of registration on the ComboMATCH Registration Trial (EAY191)

   - Participants must have a histologically confirmed non-breast solid malignancy

   - Participants must have locally advanced, unresectable, or metastatic disease in the
   opinion of the treating investigator

   - Participants must have measurable disease documented by CT or MRI. Measurable disease
   must be assessed within 28 days prior to registration. Non-measurable disease must be
   assessed within 42 days prior to registration. The CT from a combined positron
   emission tomography (PET)/CT may be used only if it is of diagnostic quality. All
   known sites of disease must be assessed and documented on the Baseline Tumor
   Assessment Form (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1).
   Participants whose only measurable disease is within a previous radiation therapy port
   must demonstrate clearly progressive disease (in the opinion of the treating
   investigator) prior to registration

   - Participants with known brain metastases must have a CT/MRI scan to evaluate for
   central nervous system (CNS) disease and show no evidence of progression within 42
   days prior to registration

   - Participants must have completed any CNS-directed therapy and/or local therapy for
   spinal cord compression at least 28 days prior to registration

   - Participants must not have spinal cord compression or brain metastases unless: (1)
   metastases have been locally treated and have remained clinically controlled and
   asymptomatic for at least 14 days prior to registration, AND (2) participant has no
   residual neurological dysfunction and has been off corticosteroids for at least 24
   hours prior to registration

   - Participants must not have leptomeningeal disease

   - Participants must have progressed within 6 months of taxane-based therapy in the
   neoadjuvant/adjuvant or metastatic setting

   - Participants must not have received any prior AKT inhibitor (e.g., capivasertib or
   ipatasertib); prior PI3K/mTOR inhibitor is acceptable

   - Participants must not be planning to receive any concurrent chemotherapy,
   immunotherapy, biologic, radiation, or hormonal therapy for cancer treatment while
   receiving treatment on this study

   - Participants must be >= 18 years of age

   - Participants must be able to swallow oral medications whole

   - Participants must have a pre-study history and physical exam done within 28 days prior
   to registration

   - Participants must have a Zubrod performance status of 0-2 within 28 days prior to

   - Participants must have adverse events resolved =< grade 1 related to any prior
   therapy, except alopecia within 14 days prior to registration

   - Participants with neuropathy must have resolved to < grade 2 within 14 days prior to

   - Leukocytes >= 3 x 10^3/uL (within 28 days prior to registration)

   - Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days prior to registration)

   - Platelets >= 100 x 10^3/uL (within 28 days prior to registration)

   - Total bilirubin =< institutional upper limit of normal (ULN) unless history of
   Gilbert's disease. Participants with history of Gilbert's disease must have total
   bilirubin =< 5 x institutional ULN (within 28 days prior to registration)

   - Aspartate aminotransferase (AST) & alanine aminotransferase (ALT) =< 3 x institutional
   ULN (within 28 days prior to registration)

   - Participants must have adequate cardiac function, class IIB (2B) or better.
   Participants with known history or current symptoms of cardiac disease, or history of
   treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac
   function using the New York Heart Association Functional Classification

   - Participants must have a measured OR calculated creatinine clearance >= 50 mL/min
   using the following Cockcroft-Gault formula. This specimen must have been drawn within
   28 days prior to registration

   - Participants with known human immunodeficiency virus (HIV)-infection must be receiving
   anti-retroviral therapy and have an undetectable viral load test on the most recent
   test results obtained within 6 months prior to registration

   - Participants with evidence of chronic hepatitis B virus (HBV) infection must have
   undetectable HBV viral load on suppressive therapy within 28 days prior to

   - Participants with a history of hepatitis C virus (HCV) infection must have been
   treated and cured. Participants with HCV infection who are currently on treatment must
   have an undetectable HCV viral load within 28 days prior to registration

   - Participants must have an electrocardiography (ECG) performed (if clinically indicated
   with a corrected QTc interval of =< 470 msec) within 28 days prior to registration

   - Participants must not have a history of allergic reactions attributed to compounds of
   similar chemical or biologic composition to ipatasertib and/or paclitaxel

   - Participants must not have an active small/large bowel inflammation such as ulcerative
   colitis or Crohn's disease

   - Participants must not have grade 2 or higher uncontrolled intercurrent illness

      - NOTE: To receive an agent, participant must not have any uncontrolled
      intercurrent illness requiring antibiotic/antiviral/antifungal therapy or
      interventional procedures. Participants with infections unlikely to be resolved
      within 2 weeks following registration should not be considered for the trial

   - Participants must not have a known grade 2 or higher uncontrolled or untreated
   hypercholesterolemia or hypertriglyceridemia

   - Participants must not have any of the following:

      - Cirrhosis at a level of Child-Pugh B (or worse),

      - Cirrhosis (any degree) and a history of hepatic encephalopathy, or

      - Clinically meaningful ascites resulting from cirrhosis. Clinically meaningful
      ascites is defined as ascites from cirrhosis requiring diuretics or paracentesis

   - Participants must not be receiving any medications or substances that are inhibitors
   or inducers of CYP3A. Treatment with strong CYP3A inhibitors or strong CYP3A inducers
   within 2 weeks or 5 drug-elimination half-lives, whichever is longer, prior to
   initiation of study drug is prohibited.

      - NOTE: Because the lists of these agents are constantly changing, it is important
      to regularly consult a frequently updated medical reference. As part of the
      enrollment/informed consent procedures, the participant will be counseled on the
      risk of interactions with other agents, and what to do if new medications need to
      be prescribed or if the participant is considering a new over-the-counter
      medicine or herbal product. The participant wallet card should be presented to
      the participant

   - Participants must not have baseline fasting glucose (after 8-hour fast) > 160 mg/dL
   (8.9 mmol/L) within 28 days prior to registration

   - Participants with known diabetes mellitus must not require insulin therapy or have a
   baseline fasting glucose >150 mg/dL (8.3 mmol/L) or high glycosylated hemoglobin
   (Hb)A1c, (>= 8.0%), suggesting poorly controlled diabetes

   - Participants who are on a stable dose of oral diabetes medication >= 2 weeks prior to
   initiation of study drug treatment are eligible for enrollment

   - Participants with a prior or concurrent malignancy whose natural history or treatment
   (in the opinion of the treating physician) must not have a potential to interfere with
   the safety or efficacy assessment of the investigational regimen

   - Participants must not have lung disease requiring active systemic therapy or placing
   participants at increased risk of toxicity related to study-directed therapy
   including, but not limited to pneumonitis, interstitial lung disease, idiopathic
   pulmonary fibrosis, cystic fibrosis, aspergillosis, active tuberculosis, or history of
   opportunistic infections (pneumocystis pneumonia or cytomegalovirus pneumonia)

   - Participants must not be pregnant or nursing. Individuals who are of reproductive
   potential must have agreed to use an effective contraceptive method with details
   provided as a part of the consent process. A person who has had menses at any time in
   the preceding 12 consecutive months or who has semen likely to contain sperm is of
   "reproductive potential". In addition to routine contraceptive methods, "effective
   contraception" also includes surgery intended to prevent pregnancy (or with a
   side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy,
   bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the

   - Participants must not have psychiatric illness/social situations that would limit
   compliance with study requirements


procedure: Biopsy

procedure: Biospecimen Collection

procedure: Computed Tomography

drug: Ipatasertib

procedure: Magnetic Resonance Imaging

drug: Paclitaxel


I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Elmira Ekinci
1 650-736-3743

New Trial Alerts